Craig M. Crews, Ph.D.

Dr. Crews is the Founder and Chief Scientific Advisor of Arvinas, as well as the L.B. Cullman Professor of Molecular, Cellular and Developmental Biology, Chemistry and Pharmacology at Yale University.

Dr. Crews’ research focuses on the design, syntheses and evaluation of small molecule regulators of intracellular protein levels and their development as novel therapeutics. YU101, a novel proteasome inhibitor from his lab, served as the lead asset of Proteolix, Inc. (purchased by Onyx in 2009; acquired by Amgen in 2013) and  became carfilzomib/Kyprolis™, which received FDA approval for relapsed/refractory multiple myeloma in 2012.